Exceptions are the resistance of organoids with mutations in the RAS/RAF pathway and sensitivity to EGF receptor-targeted therapy, the sensitivity of mutant TP53 organoids to nutlin-3a and the sensitivity of WNT ligand-dependent tumours (wildtype APC and mutant RNF43) to porcupine inhibitors38. Here, TP53 is linked to neoplasm.